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There has been a large increase in the amount of research seeking to deﬁne or diagnose Alzheimer’s disease before patients
develop dementia. If successful, this would principally have clinical beneﬁts both in terms of treatment as well as risk modiﬁcation.
Moreover, a better method for diagnosing predementia disease would assist research which seeks to develop such treatments and
risk modiﬁcation strategies. The evidence-based deﬁnition of a diagnostic test’s accuracy is fundamental to achieve the above goals
and to address this, the Cochrane Collaboration has established a Diagnostic Test Accuracy group dedicated to examining the
utility and accuracy of proposed tests in dementia and cognitive impairment. We present here the assumptions and observations
underpinning the chosen methodology as well as the initial methodological approach decided upon.
1.Introduction
Acronyms were most useful when letters and reports were
hand written or when one needed to save the ink on
the typing ribbon. Nowadays, shorthand is unnecessary,
especially when using it leads to confusion. Alzheimer’s
disease and Alzheimer’s dementia are not synonymous, but
when an author uses the acronym AD, it either suggests that
the author believes (wrongly) that they are, or we (as the
readers) are left in doubt as to which condition they were
referring to.
Alzheimer’s disease is a pathological diagnosis using a
series of standardised criteria (e.g., Khachaturian, Consor-
tium to Establish a Registry for Alzheimer’s Disease and
Reagan [1–3]) whereas Alzheimer’s dementia is a clinical
syndrome that is “possibly” or “probably” as a consequence
of Alzheimer’s disease [4]. Alzheimer’s dementia is most
commonly deﬁned in a research setting using the NINCDS-
ADRDA criteria which compared to results at autopsy,
detects Alzheimer’s disease with a sensitivity of 91–98% [5].
However, there are a group of clinical conditions probably
mediated by Alzheimer’s disease that do not satisfy the crite-
ria for Alzheimer’s dementia and these have been described
as a premanifest or incipient Alzheimer’s dementia. We
prefer the term premanifest dementia and will use this term
throughout. These conditions that will inevitably precede
dementia are often indistinguishable from those caused by
diﬀerent pathologies and have therefore all been loosely
referred to as Mild Cognitive Impairment; of which at least
16 prognostically weak deﬁnitions currently exist [6].
In Huntington’s Disease research, the availability of
an accurate diagnostic test has allowed investigation of
the clinical correlates of the disease whilst the person is
asymptomatic.Workofthisnaturehasalready,frombaseline
data alone, demonstrated neuroimaging and motor changes
[7]. The “well” individuals who will later develop Hunt-
ingdon’s disease are labelled “premanifest”, according to the
TRACK-HD programme—a large collaborative European
Research Programme which is investigating the earliest
clinical and biomarker changes (plasma proteomics and
neuroimaging) in this population. The overarching aim of
their work is to be able to deﬁne means of identifying
changes in the premanifest population that will act as
surrogate markers of an intervention’s eﬃcacy at secondary
prevention. Accordingly these interventions’ eﬃcacy can be
measured reliably before the patients manifest overt signs
of illness. In Alzheimer’s dementia research we currently
cannot describe the “premanifest” population (save for a2 International Journal of Alzheimer’s Disease
small proportion of patients with fully penetrant, autosomal
dominant mutations) and urgently need to be able to do so.
The main aims of the Cochrane Collaboration’s Diag-
nostic Test Accuracy workstream within the Dementia
and Cognitive Impairment Group are threefold. Firstly, to
scrutinise the research of tests purporting to have diagnostic
accuracy for Alzheimer’s disease in vivo, secondly, using well
rehearsed statistical techniques to derive a value for the test’s
diagnostic accuracy, and ﬁnally to highlight the deﬁciencies
(where they exist) of extant research to improve the quality
and direction of future primary research of diagnostic tests
for Alzheimer’s disease.
It should be made clear from the outset that the reviews
can only reﬂect the primary research. Whilst the ﬁrst few
reviews are all of single tests or domains of tests (episodic
memory, CSF and Plasma Aβ levels, Volumetric MRI, and
ApoE status), the reviews will not be limited exclusively
to single tests, be they clinical, genetic, or biomarker.
We are aware that the optimal and only realistic way to
make a diagnosis of premanifest dementia will be made by
combiningtestsandsuchcombinationoftests(e.g.,theCSF-
Tau/Aβ ratio) can also be reviewed by authors registering
an interest with the Cochrane Collaboration Dementia and
Cognitive Impairment Group. These combinations can be
evaluated using the DTA methodology described here. It is
hopedalsothatbydemonstratingtheDiagnosticAccuracyof
single tests through these reviews, this will help researchers
to assemble test batteries and biomarker panels in the
future from the strongest possible evidence base. Finally, the
groups work is not limited to Alzheimer’s disease, and we
will welcome reviews on other forms of neurodegenerative
disease both in their premanifest stages as well as a test or
test batteries ability to distinguish between diﬀerent types of
dementia.
With that said, the following section describes the
assumptions and observations that we have had to make and
the methodology that will be enacted in an upcoming series
of diagnostic test accuracy reviews by our group and its col-
laborators. This methodology describes the methodology for
identifyingAlzheimer’sdiseaseinpatientsbeforeAlzheimer’s
dementia develops and is applicable to both single tests as
well as scrutiny of combinations of tests.
2. Assumptions andObservations
2.1. Assumptions
2.1.1. Assumption no. 1: Alzheimer’s Dementia Does Not
Develop Overnight. It is assumed that every patient who
develops Alzheimer’s dementia has to pass through a pro-
dromal or incipient stage of mild cognitive impairment
as described by various authors using several deﬁnitions
[6]. The most common presentation for a patient with
premanifest Alzheimer’s dementia is a subjective episodic
memory complaint, which is then diagnosed as mild cogni-
tive impairment after an objective battery of neuropsycho-
logical tests demonstrate age-matched deﬁciencies. However
as Matthews et al. described, these deﬁnitions hold little
prognostic signiﬁcance with considerable variations in the
l e v e lo fi m p a i r m e n ta n do u t c o m ea tt w oy e a r s[ 6]. Most
deﬁnitions of mild cognitive impairment are cross sectional
which over time may develop along one of ﬁve clinical
courses. Though these courses are not necessarily speciﬁc to
any one disease or illness trajectory. For example, depression
or other psychiatric illness may exhibit courses 3, 4, and 5
below.
(1) Continued deterioration in cognition and functional
decline to satisfy criteria for Alzheimer’s dementia.
(2) Conversion to another subtype of dementia, for
example, Lewy body or vascular dementia.
(3) Continued deterioration in cognition which does not
go on to satisfy criteria for a dementia.
(4) No conversion, but stability of deﬁcit with no recov-
ery or progression.
(5) Recovery of cognitive abilities.
2.1.2. Assumption no. 2: Risk Factor Modiﬁcation Will Work
B e s tE a r l yi nt h eD i s e a s eC o u r s e . There has been high quality
evidence produced of late that suggests modiﬁcation of
identiﬁed epidemiological risk factors for dementia (e.g.,
decreased oestrogen levels in the menopause [10, 11])
have little beneﬁt and indeed may have safety concerns as
treatmentsoncedementiahasdeveloped[12].Thisandother
similar observations have led to the belief that there may well
be a critical window, earlier in the course of the underlying
disease, for intervention or risk factor modiﬁcation which
may include optimising cardiovascular health, increasing
exercise, minimising the risk of depression, improving diet,
increasing intellectual activity and reducing the risks for
diabetes and stroke [13].
2.1.3.Assumptionno.3:PatientsAskingforHelpWanttoKnow
What Is Causing Their Symptoms. People who have capacity
and knowledge that they have premanifest Alzheimer’s
dementia will be in a position to create lasting powers of
attorneys, advanced directives and engage in ﬁnancial, social
and lifestyle planning whilst well. Therefore, it is further
assumed that there is merit for the patient in identifying
Alzheimer’s disease prior to dementia developing. They also
have the opportunity to make advanced decisions regarding
engaging in clinical research.
2.1.4. Assumption no. 4: Disease Modifying Drugs Will
Probably Work Best in Early Disease. Common sense dictates
the earlier one starts a course of treatment for any disease
the better, though being mindful of any side eﬀects that may
outweigh the initial beneﬁts. No potentially disease modify-
ingtherapiesforAlzheimer’sdiseasehavedemonstratedclear
eﬃcacyinlatestageclinicaltrialsinpatientswithAlzheimer’s
dementia, though several still retain promise [14]. Whilst
this may be due to the drugs simply not working, the targets
being wrong or the tools to measure eﬀect being insensitive
to change; it is also possible that these drugs will only work
when the disease process is less advanced. This concept hasInternational Journal of Alzheimer’s Disease 3
Table 1: Advantages and disadvantages of diﬀerent approaches to developing an accurate diagnostic test.
Advantages Disadvantages
Single test
Fast and often easy to perform.
Acceptable to the patient
Often inexpensive
Reproducible and quantitative
The Diagnostic Odds Ratio (DOR) may not be
clinically signiﬁcant with only one test in such a
complex disorder
Results may only be signiﬁcant in a highly deﬁned
population where pre-test probability is already high
Multiple tests
More tests should each add incremental beneﬁt to
the constituent single tests and increase DOR
accordingly
C a nc o m b i n et e s t sf r o md i ﬀerent domains, for
example genetic, clinical, radiological, and
proteomic
Patient must undergo many tests to complete the
battery
Much research is required before these batteries are
available
May be expensive when including speciﬁc assays and
imaging
Results may only be signiﬁcant in a deﬁned population
where pretest probability already high
Consensus
Such criteria are easy to produce as do not rely on
any systematic, unbiased and comprehensive
literature review or testing. Such criteria have
already been described [8, 9]
While these criteria are produced and highlight the
need for validation, they are often accepted as being
valid before this process is undertaken or completed
They tend to represent a series of well educated, best
guesses. Diagnostic criteria then need testing but
application of consensus criteria tends to be piecemeal
due to multiple “either/or” criteria. Lack the rigour of
well deﬁned tests with thresholds and inherent
objectivity
Most require many tests and time from clinical and
radiological specialists which may make it hard to
reproduce between centres
Resources required are expensive.
The need for further veriﬁcation of current criteria
have been highlighted [8, 9]
beendescribedinmultiplesclerosis,wherediseasemodifying
therapies are ineﬀective in patients whose disability has
progressed to a more severe level [15]. In essence, testing
this hypothesis will require recruiting a population who
deﬁnitelyhaveearlystagediseasetobeabletodevelopdisease
modifying drugs and thereafter use this population as the
target for the clinical intervention. Such intervention may
lead to the secondary prevention of Alzheimer’s dementia by
manipulating the progression of the predementia pathology;
with great human, social, and economic beneﬁt.
3. Observations
3.1. Observation no. 1: The Gold Standard for Diagnosis. The
development of a new diagnostic test for any condition is
predicated on the ability to determine the accuracy of the
new or index test against the gold or reference standard. This
creates problems speciﬁc to Alzheimer’s disease in that there
is no in vivo gold standard, currently its premortem presence
is “probable” or “possible” based on an array of symptoms
described as Alzheimer’s dementia and neuroimaging ﬁnd-
ings.Itisworthconsideringthattheapplicabilityandaccept-
abilityofclinicalcriteriasuchasNINCDS-ADRDAarepartly
based on their concordance with pathological studies. Brain
biopsy (the means to achieving the gold standard) is not
ethical for this purpose unlike other invasive gold standard
tests (e.g., liver biopsy to determine the accuracy of ﬁbroscan
for cirrhosis). As the aim of the Cochrane reviews are to
accurately diagnosis disease before dementia develops, the
fact that a patient develops Alzheimer’s dementia (NINCDS-
ADRA criteria) is taken as ipso facto proof that at the point of
testing, disease was present. We recognise that an alternative
reference standard is needed to be used and this choice was
subject to much debate and discussion by the Cochrane
Dementia and Cognitive Impairment Editors. We hope that
over time a better reference or gold standard will emerge,
until such time though and with inherent limitations, the
conversion to NINCDS-ADRDA Alzheimer’s dementia will
be used as the gold standard.
3.2. Observation no. 2: The Gold Standard for Alzheimer’s
Disease. Accepting the assumption that there is a group
of patients at the predementia stage of Alzheimer’s disease
manifesting cognitive impairment and that there are cur-
rently no means to aﬀect the trajectory of their disease
then conventionally, it is assumed that the development of
Alzheimer’s dementia represents the necessary level of proof
that at the pre-dementia stage they had Alzheimer’s disease.
If this is accepted, then this overcomes the problem of the
indextestandreferencetestbeingseparatedovertime.Again,
although not ideal, it is at this stage considered the optimal
solution to the deﬁnition of a gold standard. Accordingly, the
reference standard is the development of clinically diagnosed
Alzheimer’s dementia or other dementias depending upon4 International Journal of Alzheimer’s Disease
the aims of speciﬁc reviews. This, however, does create
problems considering whether the test is actually diagnostic
or prognostic. If it is the latter, then we are asking whether
the test at baseline predicts a pathway of decline, stability
or improvement. However in the context of the Cochrane
Diagnostic Test Accuracy reviews we are only interested in
the ability of the test to identify underlying Alzheimer’s
disease and therefore be associated with the development of
Alzheimer’s dementia. It has no bearing what the prognosis
(clinical, behavioural or functional) of the Alzheimer’s
disease is for any given individual who returns a positive test
but rather whether or not they have Alzheimer’s disease in
their brain conﬁrmed by the test in question.
4.The Diagnostic Test Accuracy Process—What
IsBeingProposedasaMethodology?
There are three stages in developing clinically applicable
diagnostic tests or criteria for premanifest Alzheimer’s
dementia (Table 1).
(1) The testing of single or individual diagnostic tests
which may be laboratory based, clinical, genetic or
radiological in nature.
(2) Applying diagnostic test accuracy statistical enquiry
on a battery or collection of the above tests (e.g.,
Devanand et al. [16]) akin to the development of the
antenatal triple test for Down’s Syndrome.
(3) Consensus statement by clinical specialists using
what the assembled and invited experts deem to
be the most promising imaging, neuropsychological
and laboratory tests. For example those described by
Tabert et al. and Dubois et al. [8, 9]
The remainder of this paper will focus on the eﬀorts of
the Cochrane Collaboration to determine the accuracy of a
single diagnostic test. It is recognised that it is highly unlikely
that one test for a complex disorder will have suﬃcient
diagnostic accuracy however, each test will be a constituent
of a battery that may be developed from the strongest
candidates be they biomarker, genetic, or clinical. Over time
the same methodology will be applied to test batteries as and
when they arise. As the Cochrane Collaboration is widely
known for its reviews of randomised controlled trials (which
helped in the drive towards the CONSORT criteria for the
reporting of clinical trials) the Diagnostic Test Accuracy
review will have the following quality features as set out in
the Cochrane Collaborations DTA Handbook [17]
(1) Careful delineation of the diagnostic question.
(2) Systematic searching.
(3) Making comparisons between tests concerning their
global accuracy.
(4) Estimating the accuracy of a test operating at a
particular threshold.
(5) Understanding why the results of studies vary.
The purpose of a Cochrane Diagnostic Test Accuracy
review is to use meta-analysis techniques to establish a
conﬁdence around test accuracy which informs diagnosis of
theconditioninquestion.Thisisdonebyusingameticulous,
objective search strategy in order to identify data from high
quality studies which can be combined in meta-analysis.
The principle of this Diagnostic Test Accuracy review
methodology is to look for studies which document the
test of interest in patients with any of the deﬁnitions of
Mild Cognitive Impairment and then compare the results
of the test between those who convert to Alzheimer’s
dementia and those with diﬀerent outcomes, in order to
determine its diagnostic accuracy when applied at the Mild
Cognitive Impairment stage. The undertaking of a successful
Diagnostic Test Accuracy review requires a clear description
of the studies suitable for inclusion before the search, to keep
bias to a minimum and to ensure only the studies of highest
quality are analysed.
In order to achieve the objectives of a DTA review, three
major points have to be deﬁned.
(1) The Test to Be Assessed
(a) This can include plasma, urine or cerebrospinal
ﬂuid biomarkers and genetic, radiological and
well deﬁned neuropsychological assessments.
As well as combinations of these.
(2) The Population to Study
(a) We concluded that the tests should have been
applied in any of the referenced deﬁnitions of
cognitive impairment believed to be due to
neurodegeneration [6]. Only by including all
such deﬁnitions can we deﬁne the tests ability
to identify Alzheimer’s disease from the absence
of neurodegenerative disease, but also its ability
to identify which type of neurodegenerative
disease is present.
(3) The Condition under Interest
(a) It is a dilemma that there is no “gold standard”
ante mortem diagnostic test for Alzheimer’s
disease. Post-mortem provides an apparently
deﬁnitivediagnosishoweverintheextantlitera-
ture, few baseline biomarker levels are recorded
in those individuals who then have a post
mortem. For future studies, the reference stan-
dard will be conversion to Alzheimer’s demen-
tia based on the NINCDS-ADRDA criteria,
which is “probably” or “possibly” a result of
Alzheimer’s disease. This of course implies a
restricted view of the outcome to one par-
ticular form of dementia. It could be argued
that a broader concept of dementia would be
acceptable as this is what is (in eﬀect) most
relevant to the patient, their carer and their
doctor. This is acceptable as long as each review
explicitly states the ﬁnal condition of interest.International Journal of Alzheimer’s Disease 5
The Cochrane Collaboration Dementia and
Cognitive Impairment DTA Group is not only
interested in DTA’s for Alzheimer’s disease but
also reviews for all other dementias and neu-
rodegenerativediseaseassociatedwithcognitive
impairment.
A sensitive search strategy is then employed to form the
basis of the systematic review. After independent assessment
for inclusion in the DTA review, the results are analysed.
The analysis of DTA reviews is more challenging than
with intervention reviews due to the binary classiﬁcations
of sensitivity and speciﬁcity and the tradeoﬀ between the
two measures. The statistical method behind combining the
results is described in each review and the data from the
two-by-two tables will be used to calculate the sensitivity,
speciﬁcity, positive and negative likelihood ratios, and diag-
nostic odds ratio for each study. Individual study results are
presented graphically by plotting estimates of sensitivities
and speciﬁcities in Receiver Operating Characteristic (ROC)
space. If more than one threshold is reported by the study
authors, then the two-by-two table for one threshold will be
chosen to incorporate in the meta-analysis.
5. Summary of Difﬁculties andDilemmas with
DiagnosticTest AccuracyReviews in
Alzheimer’sDisease
The main diﬃculties to be faced are threefold
(1) The use of clinical criteria occurring after the test as a
gold standard.
(2) The reliability of the criteria for participant inclusion
in studies.
(3) The relevance of the test of interest and the deﬁned
population.
The most accurate reference standard would be to use
Alzheimer’s disease diagnosed by brain biopsy in order to
combat the current lack of an ante-mortem “gold standard”
test. However, this is currently unethical in the live patient
purely for the purpose of research. Also important are the
multiple deﬁnitions for the premanifest stage of Alzheimer’s
dementia. The criteria to diagnose MCI vary and are not
uniformly applied, resulting in a dissimilar predictive power
for progression to Alzheimer’s dementia between deﬁnitions
[6]. In other words, each deﬁnition of a clinical state—when
deﬁned gives a diﬀerent pretest probability for Alzheimer’s
disease. This will lead to heterogeneity in the review which
will be documented and explained where possible.
An accurate diagnostic test for Alzheimer’s disease in
the patient with premanifest Alzheimer’s dementia may be
imminent. However based on the methodology of the Diag-
nostic Test Accuracy review this will only be demonstrable in
a deﬁned population with diagnosed cognitive impairment.
There is an argument that those with no symptoms what-
so-ever (truly premanifest) should be targeted because the
beneﬁt of potential treatments or risk modiﬁcation will be
augmented. This will hopefully be the next step if accurate
diagnosis of disease can be achieved in the patients already
exhibiting and complaining of cognitive impairment.
6. Conclusions
The objective of this paper is to ensure that in future years
the Cochrane Collaboration will have reviewed and con-
structed a list of accurate diagnostic tests and test batteries,
such that clinicians will be able to accurately identify and
intervene with best practice in impaired patients with an
earlier disease stage prior to the development of disabling
dementia. Secondly, researchers will have a means to deﬁne a
premanifest Alzheimer’s disease population to direct disease
modifying therapies towards and, ﬁnally, we hope that in
being critical of current diagnostic test methodologies we
will have some impact on generally improving the quality of
primary research of diagnostic tests in dementia over time.
We believe that there are many approaches and dilemmas
to consider, which can only be overcome by using dispas-
sionate, unbiased, stringent, and evidence-based methods.
Using these methods (which may evolve over time), we
can optimise the chances of achieving accurate diagnosis of
Alzheimer’s disease at an earlier stage than is currently pos-
sible when the patients and their carers can derive maximal
beneﬁt from future treatments, psychosocial interventions,
as well as lifestyle changes and risk modiﬁcation.
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